Cytogenetics News and Research

RSS

Cytogenetics is a field of study that deals with chromosomes and related abnormalities. Chromosome analysis is also known as karyotyping and involves the pairing of homologous chromosomes.

Study uncovers new genetic pathways that could revolutionise acute dendritic leukaemia treatment

Acute dendritic leukaemia is a rare type of leukaemia, but one with the worst prognosis-the average patient survival rate is just 12-14 months-that is difficult to treat. Juan Cruz Cigudosa's team, from the Spanish National Cancer Research Centre's Molecular Cytogenetics Group, has for the first time sequenced the exome -the coding, or protein-generating, regions of the genome- of dendritic cell leukaemia.

24 Oct 2013

eXtasy software suite quickly and accurately traces origins of genetic disorders

In a bioinformatics breakthrough, iMinds - STADIUS - KU Leuven researchers have successfully applied advanced artificial intelligence to enable the automated analysis of huge amounts of genetic data.

23 Oct 2013

CNIO researchers perform first exome sequencing for non-infiltrating bladder cancer

Bladder cancer represents a serious public health problem in many countries, especially in Spain, where 11,200 new cases are recorded every year, one of the highest rates in the world. The majority of these tumours have a good prognosis -- 70-80% five-year survival after diagnosis -- and they do not infiltrate the bladder muscle at the time of diagnosis -- in around 80% of cases.

14 Oct 2013

Current criteria for ALK positive lung cancer needs to be redefined

A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. The findings suggest that doctors should look closer at borderline or atypical ALK-negative cases, and could widen the population of lung cancer patients offered treatment with crizotinib or other ALK-inhibitor drugs.

12 Sep 2013

Research findings could lead to new therapeutic approaches for liver cancer

Liver cancer (Hepatocellular Carcinoma, HCC) usually arises as the result of a chronic, inflammatory liver disease. The most common causes here are excessive alcohol consumption as well as a high-fat diet and also chronic infection with the hepatitis viruses B and C. In the course of the inflammatory process, the liver cells (hepatocytes) die more frequently due to programmed cell death.

30 Aug 2013

Study reports high survival rates for children with rare subtype of leukaemia

A pioneering genetic study means that children with a rare subtype of leukaemia have 75% less chance of their leukaemia recurring.

13 Aug 2013

New automated stainer for high throughput staining launched by Thermo Scientific

This new advanced automated stainer offers significant improvements in workflow optimization, particularly when multiple protocols are used. It has been intelligently designed to be easier to use than ever, with a new touch screen interface and intuitive software.

2 Aug 2013

OGT to release new CytoSure Consortium Cancer +SNP array for CNV and LOH detection

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, will launch its new CytoSure™ Consortium Cancer +SNP array (4x180k) at the Cancer Cytogenomics Microarray Consortium (CCMC) and Cytogenomics Array Group (CAGdb) combined meeting in Chicago on the 5th- 7th August, booth 4.

From Oxford Gene Technology 30 Jul 2013

NeoGenomics launches clinical molecular tests for comprehensive profiling of MDS

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a number of clinical molecular tests for the comprehensive profiling of myelodysplastic syndrome.

25 Jul 2013

Leica Biosystems announces acquisition of Kreatech Diagnostics

Leica Biosystems announced that it has acquired Kreatech Diagnostics, a privately-held provider of DNA fluorescent in-situ hybridization probes and target labeling reagents for microarrays.

9 Jul 2013

Transgenomic launches new mutation detection test for patients with metastatic colorectal cancer

Transgenomic, Inc. today announced the global, commercial availability of CRC RAScan, a new mutation detection test to screen patients with metastatic colorectal cancer for RAS mutations (KRAS and NRAS).

16 May 2013

Non-invasive prenatal genetic screening: an interview with Dr. Charles Strom, Senior Medical Director, Quest Diagnostics

A new category of non-invasive genetic screening tests is gaining a great deal of interest in the medical field – including from Quest Diagnostics -- for its potential to help screen women during pregnancy for genetic abnormalities known as trisomies, the most common of which is Down syndrome.

From Quest Diagnostics 13 Mar 2013

Genetic testing expansion results in urgent need for national policy

The Royal College of Pathologists of Australasia (RCPA) has announced new findings from nationwide research on the country’s genetic testing. The RCPA was contracted in 2012 by the Department of Health and Ageing to conduct its second survey on genetic testing. The findings were analysed by spokesperson on genetic testing for the RCPA, Professor Graeme Suthers, and Dr Kym Mina, Genetic Pathologist and Project Officer for the survey.

22 Feb 2013

NeoGenomics launches FISH assay for surveillance of patients with Barrett's Esophagus

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today it has validated and launched a laboratory developed Fluorescent in Situ Hybridization assay for the surveillance of patients with Barrett's Esophagus.

17 Dec 2012

UNM study to understand why and how DNA repair mechanisms go awry in cancer cells

DNA, like houses and cars, needs ongoing maintenance. Rays of ultraviolet sunlight, chemical pollutants and normal biochemical processes in the cell can damage it. Cells routinely repair this damage before making proteins or copying DNA for cell division. The repairs are remarkably accurate in normal cells but cancer cells make far more mistakes in fixing their DNA.

11 Dec 2012

New prenatal genetic test results in more clinically relevant information

A large, multi-center clinical trial led by researchers from Columbia University Medical Center (CUMC) shows that a new genetic test resulted in significantly more clinically relevant information than the current standard method of prenatal testing.

6 Dec 2012

Studies provide first clues of balanced de novo chromosomal rearrangements

Whole genome sequencing of the DNA code of three prenatal samples provided a detailed map of the locations of their chromosomal abnormalities in 14 days, scientists reported today at the American Society of Human Genetics (ASHG) 2012 meeting in San Francisco.

8 Nov 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

28 Sep 2012

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML).

12 Sep 2012